Congress quietly shifts diagnostic test oversight from FDA to labs themselves

What it does

This bill creates a new regulatory framework for laboratory-developed tests (LDTs)—diagnostic tests designed and performed within individual clinical labs—requiring them to demonstrate analytical and clinical validity before use. Labs must register tests in a centralized database, report serious errors within 5 days, and may seek optional third-party validation (including from the FDA) to confirm their tests meet standards. The bill shifts LDT oversight from the FDA's device-regulation authority to CLIA (the Clinical Laboratory Improvement Amendments), keeping tests under lab-based regulation rather than treating them as commercial medical devices.

Why we flagged it

The bill's core mechanism is to exempt laboratory-developed tests from FDA device regulation and create a parallel CLIA-based approval pathway with optional third-party validation. This is a structural deregulation that benefits labs and diagnostic companies by reducing FDA oversight burden, framed as 'enhancing' clinical laboratory innovation.

What the text implies

• Labs can self-attest to test validity without mandatory third-party review; the 'applicable standard' is met if a lab documents its own evidence, making validation largely self-policing until HHS challenges the test.
• The centralized database is designed to be transparent to 'stakeholders' but protects trade secrets and confidential commercial information, limiting public visibility into which tests are actually in use and their performance data.
• FDA is explicitly barred from enforcing device standards on LDTs even if they modify FDA-approved devices, creating a regulatory gap where a test using an approved device component can operate under weaker CLIA rules.
• Third-party validators (including the FDA itself) must complete review within 60 days or the lab can resubmit 'without prejudice,' creating a potential loop where labs shop for favorable validators or exhaust reviewers.
• Companion diagnostics (tests required for drug approval) can now be validated as LDTs with third-party affirmation instead of FDA approval, potentially weakening the link between drug and diagnostic oversight.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens gain transparency (centralized test registry, error reporting) and a safety floor (analytical/clinical validity requirements), reducing risk of unvalidated diagnostic tests entering clinical use. However, the framework is permissive: labs can perform tests without third-party validation if they self-attest to validity, and the bill explicitly bars the FDA from enforcing device standards on LDTs, potentially weakening oversight of high-risk tests. The balance between access and safety is

Who stands to gain

• Clinical laboratory operators (especially large, multi-lab corporate entities with common ownership)
• In vitro diagnostic device manufacturers (whose devices can be modified for LDT use without FDA over
• Third-party validation organizations (newly created market for supplemental affirmations)
• Diagnostic test developers operating within labs (reduced regulatory burden vs. FDA device pathway)

Named in the bill

HHS (Secretary), FDA (Food and Drug Administration), CMS (Centers for Medicare and Medicaid Services), CDC (Centers for Disease Control and Prevention), New York State Department of Health, MolDX Program, Clinical laboratories, Laboratory-developed tests (LDTs), Third-party validators, Pharmaceutical companies (companion diagnostics)

Where it stands

• May 19, 2026 — Introduced · Congress.gov: “Introduced in House”
• May 19, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 7 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $6,593,500 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

Neal Dunn, the sponsor, reported $438,583 in PAC receipts in the 2026 cycle. $2,500 of that came from 1 PAC tied to these lobbying clients.

• American Medical Association — $5,643,000 on 2 filings
• Quest Diagnostics Incorporated — $470,000 on 1 filing
• Laboratory Corporation of America Holdings — $270,000 on 1 filing
• Laboratory Corporation of America Holdings — $110,000 on 1 filing
• Association for Molecular Pathology — $70,500 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.